Skip to main content
Defiance International

Published study records

Study records.

Identifier-confirmed and citation-only records have not passed evidence or citation verification. These checks do not establish evidence strength, efficacy, safety, or suitability.

Read each study in its experimental context. A shared molecule name or database link does not establish that our material matches a study's formulation, composition or preparation. Study findings are not measurements of our inventory, promises of a biological result or authorization to use our materials in humans or animals. Actual Product specifications and lot reports are separate records.

Study record counts

68,366 study records.

407 evidence-verified · 10,493 citation-verified · 57,416 identifier-confirmed · 50 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • Human research: 689
  • In vitro: 2,868
  • In vivo/preclinical: 3,719
  • Review/meta-analysis: 3,624
  • Other: 0
Filter study recordsReset filters

Filtered results

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2017

Paradoxical response reversal of top-down modulation in cortical circuits with three interneuron types.

eLife · 2017

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not reported in the declared source.

Study design

Not reported in the declared source.

Participants or experimental system

Not reported in the declared source.

Study scale

Not reported in the declared source.

Intervention or exposure

Not reported in the declared source.

Comparator

Not reported in the declared source.

Outcomes examined

Not reported in the declared source.

Key findings

Under a low baseline activity condition, SST is inhibited and E and PV are slightly disinhibited.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2017

Effects of cerebrolysin on nerve growth factor system in the aging rat brain.

Restorative neurology and neuroscience · 2017

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

The aim of the present study was to examine the age-related modifications of endogenous neurotrophin systems in the brain of male Wistar rats and the effects of CBL on learning and memory as well as the levels neurotrophins and their receptors.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Old (23–24 months) and young (2–3 months) male Wistar rats were used for the study.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2017

Quantitative real-time imaging of glutathione

Nature communications · 2017

Study scale: In each group, >10,000 cells were initially analysed using FACS.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

To assess whether RT probe binds to any proteins or reacts with free cysteine residues in some proteins that may interfere with the final ratio readouts, we incubated RT with cell lysate, which was dialyzed using a 3 K cut-off membrane to remove all small molecules including GSH, and observed no significant changes in fluorescent signal ratios even at the highest lysate concentration shown (protein concentration is 36 mg ml−1 based on a BCA assay), suggesting that there is no non-specific interactions or reactions between cellular proteins and RT which could significantly change the ratio readouts (Fig. 2a).

Study design

Glass bottom dishes were used for cell culture due to confocal scanning requirements.

Participants or experimental system

Cell staining solution was made by diluting 100 μM of RT probe in DMSO with a suitable imaging buffer for a final probe concentration of 1 μM. DMEM was used as the imaging buffer in this contribution if not otherwise specified.

Study scale

In each group, >10,000 cells were initially analysed using FACS.

Intervention or exposure

Cells were treated with RT-AM (1 μM with 1% DMSO in DMEM) for 10–15 min before imaging.

Comparator

Not reported in the declared source.

Outcomes examined

At day 5 aggregates were gently collected, sieved through a reversible strainer and transferred into matrigel-coated plates with neural proliferation medium.

Key findings

Here, we report a reversible reaction-based fluorescent probe, designated as RealThiol (RT), that can quantitatively monitor the real-time glutathione dynamics in living cells.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2017

Humanin G (HNG) protects age-related macular degeneration (AMD) transmitochondrial ARPE-19 cybrids from mitochondrial and cellular damage.

Cell death & disease · 2017

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Cell viability levels of normal and AMD cybrids were measured using both the MTT and Trypan blue dye exclusion assays.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2016

Entinostat up-regulates the CAMP gene encoding LL-37 via activation of STAT3 and HIF-1α transcription factors.

Scientific reports · 2016

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Next, we asked whether increased expression of HIF-1α was reflected by a functional activation of this transcription factor.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2016

Characterization of Na+-K+-2Cl- Cotransporter Activity in Rabbit Lacrimal Gland Duct Cells.

Investigative ophthalmology & visual science · 2016

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not reported in the declared source.

Participants or experimental system

Interlobular ducts were isolated from fresh rabbit LG tissue.

Study scale

Not reported in the declared source.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2016

Behavioral-state modulation of inhibition is context-dependent and cell type specific in mouse visual cortex.

eLife · 2016

Study scale: At each focal plane (n = 100 fields of view), 8–12 trials (60 s duration) were acquired in total darkness and 12–20 trials acquired during visual stimulation, with dark and visual stimulation trials randomly interleaved.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

In this study, we tested this hypothesis by directly comparing the locomotion responses of excitatory and inhibitory neurons in darkness and during visual stimulation.

Study design

Individual periods of locomotion separated by stationary periods (epochs) were divided into odd and even epochs and mean LMIs were calculated for each context (darkness and visual stimulation).

Participants or experimental system

We used two-photon calcium imaging to monitor the activity of excitatory neurons as well as of three non-overlapping populations of inhibitory neurons (VIP, SST and parvalbumin [PV] neurons) in layer 2/3 and layer 4 of V1 in awake behaving mice.

Study scale

At each focal plane (n = 100 fields of view), 8–12 trials (60 s duration) were acquired in total darkness and 12–20 trials acquired during visual stimulation, with dark and visual stimulation trials randomly interleaved.

Intervention or exposure

Adeno-associated viruses (AAVs) were injected using a pipette with 20 μm tip diameter (Nanoject, Drummond Scientific, PA) at a speed of 10 nl min−1 at three different depths (around 250, 400, and 600 μm deep; 50 nl per site).

Comparator

Not reported in the declared source.

Outcomes examined

We compared the modulation of neuronal activity by locomotion in the mouse primary visual cortex (V1), between two different sensory contexts: darkness and visual stimulation.

Key findings

Context-dependent locomotion responses were found in each cell type, with the highest proportion among SST neurons.

Limitations and uncertainty

Consequently, potential confounding factors in the present study would be (1) different intracellular calcium dynamics in different types of inhibitory neurons as well as (2) a higher increase of cytosolic free calcium concentration for the same number of spikes during locomotion compared to stationary periods.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2016

Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model.

Cellular and molecular gastroenterology and hepatology · 2016

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Mice with hPepT1 overexpression in intestinal epithelial cells (transgenic [TG]) or PepT1 (PepT1-knockout [KO]) deletion were used and CAC was induced by azoxymethane/dextran sodium sulfate.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2016

VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.

Journal of neuroinflammation · 2016

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Here, we investigated the involvement of VPAC1 in the development of EAE using a VPAC1-deficient mouse model.

Study design

Not reported in the declared source.

Participants or experimental system

EAE was induced in wild-type (WT) and VPAC1 knockout (KO) mice using myelin oligodendrocyte glycoprotein 35–55 (MOG35–55), and clinical scores were assessed continuously over 30 days.

Study scale

Not reported in the declared source.

Intervention or exposure

Two hundred nanograms of Pertussis toxin (List Biological Laboratories) was administered intraperitoneally (i.p.) to the mice on the immunization day as well as 2 days later.

Comparator

The percent donor composition was determined by measuring the percentage of CD45.2 (donor) vs. CD45.1 (recipient) in whole blood cells in the recipient mice before EAE induction.

Outcomes examined

The contribution of VPAC1 expression in the immune system to the development of EAE was evaluated by means of adoptive transfer and bone marrow chimera experiments.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

In our studies with a VPAC1 antagonist treatment, a long-term administration before EAE induction led to a lack of EAE similar to that found in VPAC1 KO mice.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2016

VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model.

Scientific reports · 2016

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

In this sense, we investigated whether the in vivo treatment with VIP contributes to an immunosuppressant local microenvironment associated with an improved pregnancy outcome in the CBA/J × DBA/2 resorption prone model.

Study design

IL-10 production was quantified in macrophages of pregnant CBA/J females after in vivo treatment with PBS or VIP before and after efferocytosis.

Participants or experimental system

Mice were bred and maintained on a 12:12 h light–dark schedule in the Central Animal Care facility at the School of Exact and Natural Sciences, University of Buenos Aires (FCEyN-UBA).

Study scale

Not reported in the declared source.

Intervention or exposure

CBA/J × DBA/2 pregnant mice were treated in vivo with VIP or PBS, as described, and at day 8.5 the implantation sites were obtained and Foxp3/RORγt expression ratio was evaluated by RT-PCR.

Comparator

As shown in Fig. 5A, the control mice that were not treated with VIP had higher levels of IL-12 while the CBA/J group treated with VIP did not modulate IL-12 levels (Fig. 5A).

Outcomes examined

First of all, we studied the expression of VIP and its high affinity receptors (VPAC1 and VPAC2) in viable implantation sites.

Key findings

Pregnancy induced the expression of VIP, VPAC1 and VPAC2 in the uterus from CBA/J × DBA/2 mating females on day 8.5 of gestation compared with non-pregnant mice.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: Human research · Verification: Evidence verified by machine against declared source

  • 2016

Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.

Stroke · 2016

Study scale: A total of 208 patients were enrolled in this study between April 2008 and September 2010.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

The aim of this trial was to investigate whether stroke patients who receive Cerebrolysin show improved motor function in the upper extremities at day 90 compared with patients who receive a placebo.

Study design

This study was a prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study.

Participants or experimental system

Patients were treated with Cerebrolysin (30 mL/d) or a placebo (saline) once daily for 21 days, beginning at 24 to 72 hours after stroke onset.

Study scale

A total of 208 patients were enrolled in this study between April 2008 and September 2010.

Intervention or exposure

The study medication was administered once daily for 21 days as an intravenous infusion for 20 minutes, beginning at 24 to 72 hours after stroke onset.

Comparator

This prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study compared the effects of 30 mL Cerebrolysin versus placebo during early rehabilitation after stroke.

Outcomes examined

The primary end point was the Action Research Arm Test score on day 90.

Key findings

The nonparametric effect size on the Action Research Arm Test score on day 90 indicated a large superiority of Cerebrolysin compared with the placebo (Mann–Whitney estimator, 0.71; 95% confidence interval, 0.63–0.79; P<0.0001).

Limitations and uncertainty

Because this study was exploratory and had a relatively small sample size, the results should be confirmed in a large-scale, randomized clinical trial.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2016

Human cathelicidin, LL-37, inhibits respiratory syncytial virus infection in polarized airway epithelial cells

BMC research notes · 2016

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not reported in the declared source.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

The trans-epithelial electrical resistance (TEER) of five wells per treatment condition was evaluated at day 7 post-infection, and is presented as median Ω × cm2 ± SEM of five individual wells per treatment condition, with the range of TEER measurements indicated in parentheses.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked